Jones J M, Olman E A, Egorin M J, Aisner J
Cancer Chemother Pharmacol. 1985;14(2):172-4. doi: 10.1007/BF00434360.
Etoposide, at a dosage of 100 mg/m2 (156 mg in 250 ml 0.154 M NaCl), was instilled through a thoracostomy tube into the left pleural cavity of a 60-year-old woman with diffuse histiocytic lymphoma and a refractory, recurrent, malignant left pleural effusion. Etoposide concentrations in plasma and pleural cavity fluid were measured by a reverse-phase HPLC system with a C18-reverse phase column, a mobile phase of methanol: H2O (55:45) pumped at 1.2 ml/min, and detection by absorbance at 254 nm. Pleurodesis was successfully accomplished by this maneuver and there were no adverse clinical consequences. Absorption of etoposide from the pleural cavity was slow (approximately 0.2 ml/min). The pleural cavity exposure to etoposide, as measured by the area under the curve, was 46 times greater than if a similar dose had been given IV. Conversely, systemic exposure to etoposide, as assessed by plasma AUC, was less than 50% that associated with IV injection of a similar dose.
依托泊苷，剂量为100mg/m²（250ml 0.154M氯化钠中含156mg），通过胸腔造瘘管注入一名60岁患有弥漫性组织细胞淋巴瘤且伴有难治性、复发性恶性左侧胸腔积液的女性患者的左侧胸腔。采用配备C18反相柱的反相高效液相色谱系统测定血浆和胸腔积液中的依托泊苷浓度，流动相为甲醇：水（55:45），流速为1.2ml/min，在254nm波长处通过吸光度进行检测。通过该操作成功实现了胸膜固定术，且未出现不良临床后果。依托泊苷从胸腔的吸收缓慢（约0.2ml/min）。通过曲线下面积测定，胸腔对依托泊苷的暴露量比静脉注射相同剂量时大46倍。相反，通过血浆AUC评估，依托泊苷的全身暴露量不到静脉注射相同剂量时的50%。
